Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Equity Income: 2022-2024

  • Crinetics Pharmaceuticals' Equity Income was N/A to -$470,000 in Q1 2024 from the same period last year, while for Mar 2024 it was -$6.7 million, marking a year-over-year change of. This contributed to the annual value of -$470,000 for FY2024, which is 90.96% up from last year.
  • Crinetics Pharmaceuticals' Equity Income amounted to -$470,000 in Q1 2024, which was up 88.81% from -$4.2 million recorded in Q4 2023.
  • Crinetics Pharmaceuticals' 5-year Equity Income high stood at -$470,000 for Q1 2024, and its period low was -$4.2 million during Q4 2023.
  • Moreover, its 3-year median value for Equity Income was -$1.0 million (2022), whereas its average is -$1.7 million.